Blockchain Registration Transaction Record

NanoViricides to Present at D. Boral Capital Global Conference 2026

NanoViricides (NNVC) to present at D. Boral Capital Global Conference on May 7, 2026. CEO Anil Diwan to hold one-on-one meetings. Lead drug NV-387 targets RSV, COVID, influenza, and Monkeypox.

This news matters because NanoViricides is developing broad-spectrum antiviral drugs that could address major public health threats like COVID-19, RSV, influenza, and even Monkeypox. The company's participation in the D. Boral Capital Global Conference signals its readiness to advance NV-387 into Phase II trials, potentially bringing a new treatment option for viral infections that currently lack effective therapies. For investors, this conference provides a key opportunity to assess the company's progress and future prospects in the antiviral space.